TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Market Closed - Deutsche Boerse AG 03:48:36 2024-06-27 pm EDT | ||
| 27.19 EUR | +0.59% |
|
| Current month | +8.67% | ||
| 1 month | +8.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 27.19 | +0.59% |
| 24-06-26 | 27.03 | +0.75% |
| 24-06-25 | 26.83 | +0.26% |
| 24-06-24 | 26.76 | -0.34% |
| 24-06-21 | 26.85 | -0.44% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 03:48 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SF75XJ |
| ISIN | DE000SF75XJ1 |
| Date issued | 2021-09-06 |
| Strike | 3,801 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.52 € |
|---|---|
| Lowest since issue | 8.25 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,778
DKK
Average target price
2,464
DKK
Spread / Average Target
+38.54%
- Stock Market
- Certificates
- Certificat
